NexusPharma is dedicated to the discovery of novel therapeutics that modulate protein-protein interactions. Novel drug candidates will be advanced into clinical development for the treatment of cancer through approaches based on non-cytotoxic mechanisms.

Applying its patented technologies discovered at Fox Chase Cancer Center, NexusPharma has discovered novel small-molecule protein-protein interaction inhibitors (PPII's) for a variety of biological targets. As a co-founder of NexusPharma, Fox Chase Cancer Center supports the development of a physiological, cost-effective platform for pre-clinical compound assessment along with other research activities at NexusPharma scheduled for the coming years.

Home | Contacts | Directions